Phase IB Study of a Galectin Inhibitor (GR-MD-02) and Pembrolizumab in Patients With Metastatic Melanoma, Non-Small Cell Lung Cancer, and Head and Neck Squamous Cell Carcinoma.

Next Previous
Trial Profile

Phase IB Study of a Galectin Inhibitor (GR-MD-02) and Pembrolizumab in Patients With Metastatic Melanoma, Non-Small Cell Lung Cancer, and Head and Neck Squamous Cell Carcinoma.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Mar 2018

At a glance

  • Drugs GR MD 02 (Primary) ; Pembrolizumab
  • Indications Head and neck cancer; Malignant melanoma; Non-small cell lung cancer
  • Focus Adverse reactions

    • Most Recent Events

    • 29 Mar 2018 Results presented in the Galectin Therapeutics media release.
    • 29 Mar 2018 According to a Galectin Therapeutics media release, company has begun enrolling cohort 3 (GR-MD-02 8 mg/kg) of the pembrolizumab which will include at least 10 patients with melanoma and additional data can be reported in mid-2018.
    • 06 Feb 2018 According to a Galectin Therapeutics media release, company expects an additional results in Summer, 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top